- Home
- OMER vs EVAC Comparison
OMER vs EVAC Comparison
Compare OMER & EVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMER
- EVAC
- Stock Information
- Founded
- OMER 1994
- EVAC 2024
- Country
- OMER United States
- EVAC United States
- Employees
- OMER N/A
- EVAC N/A
- Industry
- OMER Biotechnology: Pharmaceutical Preparations
- EVAC Fluid Controls
- Sector
- OMER Health Care
- EVAC Industrials
- Exchange
- OMER Nasdaq
- EVAC Nasdaq
- Market Cap
- OMER 513.8M
- EVAC 591.4M
- IPO Year
- OMER 2009
- EVAC 2025
- Fundamental
- Price
- OMER $8.83
- EVAC $10.04
- Analyst Decision
- OMER Strong Buy
- EVAC
- Analyst Count
- OMER 5
- EVAC 0
- Target Price
- OMER $27.50
- EVAC N/A
- AVG Volume (30 Days)
- OMER 1.7M
- EVAC 77.5K
- Earning Date
- OMER 11-13-2025
- EVAC 01-01-0001
- Dividend Yield
- OMER N/A
- EVAC N/A
- EPS Growth
- OMER N/A
- EVAC N/A
- EPS
- OMER N/A
- EVAC N/A
- Revenue
- OMER N/A
- EVAC N/A
- Revenue This Year
- OMER N/A
- EVAC N/A
- Revenue Next Year
- OMER N/A
- EVAC N/A
- P/E Ratio
- OMER N/A
- EVAC N/A
- Revenue Growth
- OMER N/A
- EVAC N/A
- 52 Week Low
- OMER $2.95
- EVAC $9.90
- 52 Week High
- OMER $13.60
- EVAC $10.17
- Technical
- Relative Strength Index (RSI)
- OMER 67.40
- EVAC N/A
- Support Level
- OMER $6.24
- EVAC N/A
- Resistance Level
- OMER $7.06
- EVAC N/A
- Average True Range (ATR)
- OMER 0.54
- EVAC 0.00
- MACD
- OMER 0.02
- EVAC 0.00
- Stochastic Oscillator
- OMER 99.65
- EVAC 0.00
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
About EVAC EQV Ventures Acquisition Corp. II Class A Ordinary Shares
EQV Ventures Acquisition Corp II is a blank check company.